Citations

Showing 10 of 108162 citations.

HER2 gene amplification and protein overexpression in uterine clear cell carcinoma and its implications in targeted immunotherapy.
Zhou, Jain, Sukov, William R. , Schoolmeester, J. Kenneth , Carter, Jodi M.

Mayo Clinic

Journal of Clinical Oncology | November 26, 2019 | Volume: 35 | Issue: 7_suppl | Pages: 29-29

10.1200/jco.2017.35.7_suppl.29 Get It

29 Background: Uterine clear cell carcinoma (UCCC) is a high-grade endometrial carcinoma. The current treatment is hysterectomy with post-operative chemotherapy and/or radiation. The 5-year disease free survival remains dismal for UCCC with 65% for early-stage and 54% for advanced stage disease. In addition, UCCC may be more resistant to chemotherapy or radiation therapy than the endometrioid subtype. The aim of the current study is to investigate the HER2 gene amplification status in UCCC and its role for targeted therapy in UCCC. Methods: Twenty-nine cases of UCCC were retrieved from surgical pathology archives of Mayo Clinic at Rochester between 2011 and 2015. All cases except one case were hysterectomy specimens. The blocks contain the most characteristic morphology of UCCC were selected and corresponding paraffin sections were subjected to fluorescent in situ hybridization for amplification of HER2 gene (Hercept, Abbott Molecular) and parallel immunohistochemical (IHC) study. Results: A total of 9 (of 29; 31%) UCCCs showed HER2 amplification and 4 (of 29; 14%) were considered equivocal for HER2 amplification by FISH. A total of 3 (10%) tumors showed 3+ HER2 overexpression while 11 (38%) UCCCs showed 2+ HER2 overexpression, 9 (31%) showed 1+ expression with the remaining cases showing no expression of HER2. Importantly, we observed significant intratumoral heterogeneity with regard to HER2 expression. Comparing the results of IHC with HER2 gene status as determined by FISH, 2 (66%) of the 3 cases that showed 3+ HER2 expression also showed amplification for HER2 by FISH, while 1 (33%) was equivocal for HER2 amplification. Of the 11 tumors that showed 2+ HER2 expression, 6 (55%) were amplified by FISH and 1 (9%) was equivocal. Conclusions: This is the largest number of UCCC cases that has been studied on the HER2 amplification and corresponding protein overexpression. Our results indicate that the HER2 overexpression is common in UCCCs and is frequently associated with HER2 amplification. These results also suggest that targeted adjuvant therapy with trastuzumab-based immunotherapy should be evaluated in patients with UCCC showing HER2 protein overexpression or HER2 gene amplification.
Effects of TTI-621 (SIRPαFc) on CD47 and serum cytokines associated with phagocytosis in subjects with relapsed, refractory hematologic malignancies: Pharmacodynamic findings from a first-in-human clinical trial.
King, Rebecca L. , Ansell, Stephen M. , Chen, Robert W., Maris, Michael B., Irwin, Meghan, Petrova, Penka S., Uger, Robert A. , Johnson, Lisa D. , Pillai, Raju K. , Flinn, Ian W. , Sievers, Eric L.

Mayo Clinic

Journal of Clinical Oncology | November 26, 2019 | Volume: 35 | Issue: 7_suppl | Pages: 112-112

10.1200/jco.2017.35.7_suppl.112 Get It

112 Background: CD47 delivers an anti-phagocytic (“do not eat”) signal by binding SIRPα on macrophages and is overexpressed on many cancers enabling immune surveillance evasion. TTI-621 is a decoy receptor that promotes phagocytosis of tumors by blocking CD47 and engaging activating FcR on macrophages. A first-in-human, phase 1a, open label, multicenter study (NCT02663518) evaluating safety and tolerability of weekly, intravenous infusions of TTI-621 was conducted. As of October 12, 2016, 18 subjects were treated with TTI-621 with doses of 0.05-0.3 mg/kg. Multiple pharmacodynamic and hematologic assessments were performed to characterize the effects of TTI-621 and better understand the mechanism of action. Methods: Serial blood draws were analyzed for CD47 receptor occupancy (RO), complete blood counts, cytokines, T cell repertoire changes and CD47, SIRPα and FcR sequences. CD47 expression, macrophage and T cell infiltration was assessed on biopsies by IHC. Results: Peripheral CD47 levels varied considerably between subjects and were inversely correlated with RO. A maximum of 80% RO was achieved on peripheral leukocytes. Circulating monocytes, neutrophils, and lymphocytes were transiently decreased at the end of the TTI-621 infusion and generally returned to baseline levels by 24 to 72 hours. Platelet counts decreased immediately after TTI-621 infusions, typically recovering to baseline levels prior to the subsequent treatment cycle. Hemoglobin levels did not meaningfully change during treatment. Cytokines associated with macrophage activation or phagocytosis, notably MIP-1α, MIP-1β, TNF-α and IP-10 were elevated in a dose dependent manner. Conclusions: Systemic administration of TTI-621 leads to CD47 blockade and dose dependent increases in cytokines associated with phagocytosis, temporally associated with reversible thrombocytopenia, suggesting enhanced macrophage mediated clearance of circulating platelets followed by a robust marrow regenerative response. Enrollment into multiple expansion cohorts addressing a wide range of hematopoietic cancers is ongoing. Clinical trial information: NCT02663518.
What’s New in Adult Reconstructive Knee Surgery
Taunton, Michael J. , Taunton, Michael J

Mayo Clinic

Journal of Bone and Joint Surgery | November 26, 2019 | Volume: 102 | Issue: 2 | Pages: 91-100

10.2106/jbjs.19.01063 | PMID 31770295 Get It

Dose Reduction for Sinus and Temporal Bone Imaging Using Photon-Counting Detector CT With an Additional Tin Filter
Voß, Benjamin, Tao, Shengzhen , Lane, John I. , Weaver, Jayse , Carlson, Matthew L. , Rajendran, Kishore , Zhou, Wei , DeLone, David R. , Fletcher, Joel G. , McCollough, Cynthia H. , Leng, Shuai

Mayo Clinic

Investigative Radiology | November 26, 2019 | Volume: 55 | Issue: 2 | Pages: 91-100

10.1097/rli.0000000000000614 | PMID 31770297 Get It

Objective The aim of this study was to quantitatively demonstrate radiation dose reduction for sinus and temporal bone examinations using high-resolution photon-counting detector (PCD) computed tomography (CT) with an additional tin (Sn) filter. Materials and Methods A multienergy CT phantom, an anthropomorphic head phantom, and a cadaver head were scanned on a research PCD-CT scanner using ultra-high-resolution mode at 100-kV tube potential with an additional tin filter (Sn-100 kV) and volume CT dose index of 10 mGy. They were also scanned on a commercial CT scanner with an energy-integrating detector (EID) following standard clinical protocols. Thirty patients referred to clinically indicated sinus examinations, and two patients referred to temporal bone examinations were scanned on the PCD-CT system after their clinical scans on an EID-CT. For the sinus cohort, PCD-CT scans were performed using Sn-100 kV at 4 dose levels at 10 mGy (n = 9), 8 mGy (n = 7), 7 mGy (n = 7), and 6 mGy (n = 7), and the clinical EID-CT was performed at 120 kV and 13.7 mGy (mean CT volume dose index). For the temporal bone scans, PCD-CT was performed using Sn-100 kV (10.1 mGy), and EID-CT was performed at 120 kV and routine clinical dose (52.6 and 66 mGy). For both PCD-CT and EID-CT, sinus images were reconstructed using H70 kernel at 0.75-mm slice thickness, and temporal bone images were reconstructed using a U70 kernel at 0.6-mm slice thickness. In addition, iterative reconstruction with a dedicated sharp kernel (V80) was used to obtain high-resolution PCD-CT images from a sinus patient scan to demonstrate improved anatomic delineation. Improvements in spatial resolution from the dedicated sharp kernel was quantified using modulation transfer function measured with a wire phantom. A neuroradiologist assessed the H70 sinus images for visualization of critical anatomical structures in low-dose PCD-CT images and routine-dose EID-CT images using a 5-point Likert scale (structural detection obscured and poor diagnostic confidence, score = 1; improved anatomic delineation and diagnostic confidence, score = 5). Image contrast and noise were measured in representative regions of interest and compared between PCD-CT and EID-CT, and the noise difference between the 2 acquisitions was used to estimate the dose reduction in the sinus and temporal bone patient cohorts. Results The multienergy phantom experiment showed a noise reduction of 26% in the Sn-100 kV PCD-CT image, corresponding to a total dose reduction of 56% compared with EID-CT (clinical dose) without compromising image contrast. The PCD-CT images from the head phantom and the cadaver scans demonstrated a dose reduction of 67% and 83%, for sinus and temporal bone examinations, respectively, compared with EID-CT. In the sinus cohort, PCD-CT demonstrated a mean dose reduction of 67%. The 10- and 8-mGy sinus patient images from PCD-CT were significantly superior to clinical EID-CT for visualization of critical sinus structures (median score = 5 ± 0.82 and P = 0.01 for lesser palatine foramina, median score = 4 ± 0.68 and P = 0.039 for nasomaxillary sutures, and median score = 4 ± 0.96 and P = 0.01 for anterior ethmoid artery canal). The 6- and 7-mGy sinus patient images did not show any significant difference between PCD-CT and EID-CT. In addition, V80 (sharp kernel, 10% modulation transfer function = 18.6 cm −1 ) PCD-CT images from a sinus patient scan increased the conspicuity of nasomaxillary sutures compared with the clinical EID-CT images. The temporal bone patient images demonstrated a dose reduction of up to 85% compared with clinical EID-CT images, whereas visualization of inner ear structures such as the incudomalleolar joint were similar between EID-CT and PCD-CT. Conclusions Phantom and cadaver studies demonstrated dose reduction using Sn-100 kV PCD-CT compared with current clinical EID-CT while maintaining the desired image contrast. Dose reduction was further validated in sinus and temporal bone patient studies. The ultra-high resolution capability from PCD-CT allowed improved anatomical delineation for sinus imaging compared with current clinical standard.
Distinct Cutoff Values of Adalimumab Trough Levels Are Associated With Different Therapeutic Outcomes in Patients With Inflammatory Bowel Disease
Park, Sang Hyoung , Kane, Sunanda V. , Papadakis, Konstantinos A. , Bruining, David H. , Faubion, William A. , Raffals, Laura E. , Pardi, Darrell S. , Tremaine, William J., Stephens, Michael C., Khanna, Sahil , Loftus, Edward V. , Loftus, Edward V , Al‐Bawardy, Badr , Aniwan, Satimai , Coelho–Prabhu, Nayantara , Kisiel, John B. , Willrich, Maria Alice V.

Mayo Clinic

Crohn's & Colitis 360 | November 26, 2019 | Volume: 1 | Issue: 3 | Pages: No page available

10.1093/crocol/otz047 Get It

Abstract Background and Aims We aimed to evaluate the relationship of serum adalimumab trough levels (ATL) with disease activity of inflammatory bowel disease (IBD) patients in a large, well-characterized referral center-based cohort. Methods We compared serum ATL between those with clinical, biochemical, or endoscopic/radiologic disease activity and those without. Results A total of 236 patients with IBD were included. Higher cutoff levels were associated with endoscopic and/or radiologic responses (cutoff value: 5.3 mcg/mL, P = 0.003) compared with improvement in C-reactive protein (cutoff value: 4.3 mcg/mL, P = 0.031). Conclusions Higher cutoff ATL was associated with endoscopic and/or radiologic response.
Psychiatric Emergencies in the Intensive Care Unit
New, Andrea M., Nelson, Sarah , Leung, Jonathan G.

Mayo Clinic

AACN Advanced Critical Care | November 26, 2019 | Volume: 26 | Issue: 4 | Pages: 285-293

10.4037/nci.0000000000000104 Get It

Intraventricular Thrombus Formation and Embolism in Takotsubo Syndrome
Ding, Katharina J., Cammann, Victoria L. , Szawan, Konrad A. , Stähli, Barbara E. , Wischnewsky, Manfred , Vece, Davide Di , Citro, Rodolfo , Sarcon, Annahita, Knorr, Maike, Heiner, Susanne, Gili, Sebastiano , Napp, L. Christian , Franke, Jennifer , Burgdorf, Christof , Köenig, Wolfgang , Kherad, Behrouz , Rajan, Lawrence, Michels, Guido, Pfister, Roman , Cuneo, Alessandro , Jacobshagen, Claudius, Karakas, Mahir , Pott, Alexander , Meyer, Philippe , Arroja, José David , Banning, Adrian , Cuculi, Florim , Kobza, Richard , Fischer, Thomas, Vasankari, Tuija , Paolini, Carla , Bilato, Claudio , Carrilho‐Ferreira, Pedro , Opolski, Grzegorz , Dworakowski, Rafał , MacCarthy, Philip , Osswald, Stefan , Galiuto, Leonarda , Chan, Christina , Bridgman, Paul , El‐Battrawy, Ibrahim , Akın, İbrahim , Gilyarova, Ekaterina, Gilyarov, Mikhail , Kozel, Martin , Widimský, Petr , Winchester, David E. , Ukena, Christian , Prasad, Abhiram , Rihal, Charanjit S. , Pinto, Fausto J. , Borggrefe, Martin, Rottbauer, Wolfgang , Katus, Hugo A. , Tschöpe, Carsten , Pieske, Burkert , Böhm, Michael , Felix, Stephan B. , Münzel, Thomas , Lüscher, Thomas F. , Ghadri, Jelena R. , Bossone, Eduardo , Templin, Christian , Gilyarov, Mikhail , Bossone, Eduardo , Citro, Rodolfo , El-Battrawy, Ibrahim , Prasad, Abhiram , Tschöpe, Carsten , Koenig, Wolfgang , Meyer, Philippe , Banning, Adrian , Kobza, Richard , Gilyarov, Mikhail , Ukena, Christian , Bilato, Claudio , Jaguszewski, Miłosz , Seifert, Burkhardt , D’Ascenzo, Fabrizio , Neuhaus, Michael, Noutsias, Michel , Airaksinen, Juhani , Kaiser, Christoph A. , Dichtl, Wolfgang , Delmas, Clément , Lairez, Olivier , Shilova, Alexandra S. , Toušek, Petr , Gałuszka, Jan , Horowitz, John D. , Mario, Carlo Di , Rihal, Charanjit S. , Crea, Filippo , Braun-Dullaeus, Ruediger Christian , Bauersachs, Johann , Hasenfuß, Gerd , Thiele, Hölger , Schunkert, Heribert , Bax, Jeroen J. , Ruschitzka, Frank T.

Mayo Clinic

Arteriosclerosis, Thrombosis, and Vascular Biology | November 26, 2019 | Volume: 40 | Issue: 1 | Pages: 279-287

10.1161/atvbaha.119.313491 | PMID 31766870 Get It

Objective: Takotsubo syndrome (TTS) is characterized by acute left ventricular dysfunction, which can contribute to intraventricular thrombus and embolism. Still, prevalence and clinical impact of thrombus formation and embolic events on outcome of TTS patients remain unclear. This study aimed to investigate clinical features and outcomes of patients with and without intraventricular thrombus or embolism. Additionally, factors associated with thrombus formation or embolism, as well as predictors for mortality, were identified. Approach and Results: TTS patients enrolled in the International Takotsubo Registry at 28 centers in Australia, Europe, and the United States were dichotomized according to the occurrence/absence of intraventricular thrombus or embolism. Patients with intraventricular thrombus or embolism were defined as the ThrombEmb group. Of 1676 TTS patients, 56 (3.3%) patients developed intraventricular thrombus and/or embolism following TTS diagnosis (median time interval, 2.0 days [range, 0–38 days]). Patients in the ThrombEmb group had a different clinical profile including lower left ventricular ejection fraction, higher prevalence of the apical type, elevated levels of troponin and inflammatory markers, and higher prevalence of vascular disease. In a Firth bias-reduced penalized-likelihood logistic regression model apical type, left ventricular ejection fraction ≤30%, previous vascular disease, and a white blood cell count on admission >10×10 3 cells/μL emerged as independent predictors for thrombus formation or embolism. Conclusions: Intraventricular thrombus or embolism occur in 3.3% of patients in the acute phase of TTS. A simple risk score including clinical parameters associated with intraventricular thrombus formation or embolism identifies patients at increased risk. Clinical Trial Registration: URL: http://www.clinicaltrials.gov . Unique identifier: NCT01947621.
Tau‐positron emission tomography correlates with neuropathology findings
Lowe, Val J. , Lundt, Emily S. , Albertson, Sabrina M., Min, Hoon‐Ki , Fang, Ping , Przybelski, Scott A. , Senjem, Matthew L. , Kantarci, Kejal , Reichard, R. Ross , Tranovich, Jessica F., Al‐Shaikh, Fadi S. Hanna , Petersen, Ronald C. , Murray, Melissa E. , Hanna Al-Shaikh, Fadi S, Min, Hoon-Ki Paul , Senjem, Matthew L , Kantarci, Kejal , Murray, Melissa E , Schwarz, Christopher G. , Boeve, Bradley F. , Jones, David T. , Knopman, David S. , Jack, Clifford R. , Dickson, Dennis W. , Lundt, Emily S

Mayo Clinic

Alzheimer's & Dementia | November 26, 2019 | Volume: 16 | Issue: 3 | Pages: 561-571

10.1016/j.jalz.2019.09.079 | PMID 31784374 Get It

AbstractIntroductionComparison of tau (flortaucipir) positron emission tomography (FTP‐PET) to autopsy is important to demonstrate the relationship of FTP‐PET to neuropathologic findings.MethodsAutopsies were performed on 26 participants who had antemortem FTP‐PET. FTP‐PET standardized uptake value ratios (SUVRs) were compared to autopsy diagnoses and Braak tangle stage. Quantitative tau burden was compared to regional FTP‐PET signal.ResultsParticipants with Braak stages of IV or greater had elevated FTP‐PET signal. FTP‐PET was elevated in participants with Alzheimer's disease. An FTP‐PET SUVR cut point of 1.29 was determined to be optimal. Quantitative measurements of hippocampal and temporal lobe tau burden were highly correlated to FTP‐PET signal (rho's from 0.61 to 0.70, P ≤ .02).DiscussionElevated FTP‐PET reflects Braak IV or greater neuropathology. Participants with primary age‐related tauopathy and hippocampal sclerosis did not show elevated FTP‐PET signal. Secondary neuropathologic diagnoses of Alzheimer's disease neuropathologic change can lead to borderline elevated FTP‐PET signal.
Clinical and volumetric changes with increasing functional impairment in familial frontotemporal lobar degeneration
Olney, Nicholas , Ong, Elise, Goh, Sheng‐Yang M., Bajorek, Lynn, Dever, Reilly, Staffaroni, Adam M. , Bock, Meredith , Chiang, Kevin, Ljubenkov, Peter A. , Kornak, John , Heuer, Hilary W. , Rascovsky, Katya, Wolf, Amelia, Bove, Jessica, Bordelon, Yvette , Brannelly, Patrick , Brushaber, Danielle , Caso, Christine, Coppola, Giovanni , Dickinson, Susan, Domoto‐Reilly, Kimiko , Faber, Kelly, Ferrall, Jessica, Fields, Julie A. , Fishman, Ann, Foroud, Tatiana M., Forsberg, Leah K. , Gearhart, Debra, Ghazanfari, Behnaz, Ghoshal, Nupur , Graff‐Radford, Jonathan, Graff‐Radford, Neill R. , Grant, Ian , Haley, Dana , Hsiung, Ging‐Yuek Robin , Huey, Edward D. , Irwin, David J. , Kantarci, Kejal , Karydas, Anna M., Kaufer, Daniel , Kramer, Joel H. , Kraft, Ruth, Kremers, Walter K. , Kukull, Walter A. , Mackenzie, Ian R. , Maldonado, Miranda, Manoochehri, Masood , McGinnis, Scott M., McKinley, Emily , Mendez, Mario F. , Miller, Bruce L. , Onyike, Chiadi U. , Pantelyat, Alexander , Pearlman, Rodney , Petrucelli, Len, Potter, Madeleine, Rademakers, Rosa , Ramos, Eliana Marisa , Rankin, Katherine P. , Roberson, Erik D. , Rogalskı, Emily , Sengdy, Pheth, Shaw, Leslie M. , Syrjanen, Jeremy A. , Tartaglia, Maria Carmela , Tatton, Nadine , Taylor, Joanne, Trojanowski, John Q. , Weıntraub, Sandra , Wong, Bonnie , Boxer, Adam L. , Rosen, Howard J. , consortia, on behalf of the ARTFL and LEFFTDS, Gearhart, Debra J, Boeve, Brad F, Irwin, David J , Hsiung, Gink-Yuek , Roberson, Erik , Miller, Bruce L , Kantarci, Kejal , Pantelyat, Alex , Tartaglia, Maria Carmela , Kremers, Walter K , Domoto-Reilly, Kimiko , Cobigo, Yann , Wang, Ping , Appleby, Brian S. , Dickerson, Bradford Clark , Fong, Jamie , Goldman, Jill , Graff‐Radford, Jonathan , Grossman, Murray , Jones, David T. , Kerwin, Diana , Knopman, David S. , Lapid, Maria I. , Litvan, Irene , Potter, Madeleine, Toga, Arthur W. , Wszołek, Zbigniew K. , Boeve, Bradley F. , consortia, on behalf of the ARTFL and LEFFTDS

Mayo Clinic

Alzheimer's & Dementia | November 26, 2019 | Volume: 16 | Issue: 1 | Pages: 49-59

10.1016/j.jalz.2019.08.196 | PMID 31784375 Get It

AbstractIntroductionThe Advancing Research and Treatment in Frontotemporal Lobar Degeneration and Longitudinal Evaluation of Familial Frontotemporal Dementia Subjects longitudinal studies were designed to describe the natural history of familial‐frontotemporal lobar degeneration due to autosomal dominant mutations.MethodsWe examined cognitive performance, behavioral ratings, and brain volumes from the first time point in 320 MAPT, GRN, and C9orf72 family members, including 102 non–mutation carriers, 103 asymptomatic carriers, 43 mildly/questionably symptomatic carriers, and 72 carriers with dementia.ResultsAsymptomatic carriers showed similar scores on all clinical measures compared with noncarriers but reduced frontal and temporal volumes. Those with mild/questionable impairment showed decreased verbal recall, fluency, and Trail Making Test performance and impaired mood and self‐monitoring. Dementia was associated with impairment in all measures. All MAPT carriers with dementia showed temporal atrophy, but otherwise, there was no single cognitive test or brain region that was abnormal in all subjects.DiscussionImaging changes appear to precede clinical changes in familial‐frontotemporal lobar degeneration, but specific early clinical and imaging changes vary across individuals.